Castle Biosciences (CSTL) Gross Margin (2018 - 2026)
Castle Biosciences (CSTL) posted Gross Margin of 77.11% for Q2 2026, up 2.19% sequentially from 75.46% in Q1 2026, and down 244.0% YoY from 53.55% in Q2 2025.
Castle Biosciences (CSTL) Gross Margin (2018 - 2026) Analysis & Trends
Castle Biosciences has reported Gross Margin for 9 years, with the latest figure at 77.11% in Q2 2026.
- Quarterly Gross Margin fell 244.0% year-over-year to 77.11% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 77.26% (down 374.0% YoY) and the FY2025 annual result came in at 79.37%, down 250.0% from the prior year.
- Gross Margin rose to 77.11% in Q2 2026 per CSTL's latest filing, from 75.46% in the prior quarter.
- Over five years, Gross Margin peaked at 83.31% in Q2 2024 and troughed at 75.17% in Q4 2022.
- A 5-year average of 78.93% and a median of 78.45% in 2023 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2022 and 2023: Gross Margin sank 886 bps in 2022, then surged 604 bps in 2023.
- Over 5 years, Gross Margin stood at 75.17% in 2022, then rose by 8 bps to 81.21% in 2023, then gained by 0 bps to 81.25% in 2024, then declined by 3 bps to 78.95% in 2025, then decreased by 2 bps to 77.11% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 77.11%, 75.46%, and 78.95% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 69.57% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 57.64% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 64.04% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 53.95% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 32.85% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | 99.91% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 66.44% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 63.29% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 33.75% |
| 10 | Castle Biosciences | 926.56 Mn | 659.75 Mn | 79.85 Mn | 77.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.11% |
| Mar 31, 2026 | 75.46% |
| Dec 31, 2025 | 78.95% |
| Sep 30, 2025 | 77.48% |
| Jun 30, 2025 | 79.55% |
| Mar 31, 2025 | 81.38% |
| Dec 31, 2024 | 81.25% |
| Sep 30, 2024 | 81.80% |
| Jun 30, 2024 | 83.31% |
| Mar 31, 2024 | 80.96% |
| Dec 31, 2023 | 81.21% |
| Sep 30, 2023 | 81.59% |
| Jun 30, 2023 | 77.94% |
| Mar 31, 2023 | 75.78% |
| Dec 31, 2022 | 75.17% |
| Sep 30, 2022 | 76.06% |
| Jun 30, 2022 | 77.94% |
| Mar 31, 2022 | 77.86% |
| Dec 31, 2021 | 81.64% |
| Sep 30, 2021 | 80.83% |